Mirvetuximab Soravtansine: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis.PloS one · 2024
   Pooled it
2. Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026
   Review
3. Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases.The journal of pathology. Clinical research · 2026
   Article
4. Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
   Review
5. NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
   Article
6. Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.International journal of biological sciences · 2026
   Review
7. Cardiotoxicity associated with anticancer therapies for gynecological tumors.Frontiers in cardiovascular medicine · 2026
   Review
8. Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics.Archives of pharmacal research · 2026
   Review
9. Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer.Frontiers in immunology · 2026
   Review
10. Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age.mAbs · 2025
    Review
11. The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis.Discover oncology · 2025
    Article
12. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.Journal of hematology & oncology · 2025
    Review
13. Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins.Nature chemical biology · 2025
    Article
14. Lysosomal Cathepsin S Escape Facilitates Near Infrared Light-Triggered Pyroptosis Via an Antibody-Indocyanine Green Conjugate.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
15. The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025
    Review
16. Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer.Oncology reports · 2025
    Review
17. Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer.American journal of ophthalmology case reports · 2025
    Article
18. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.Cancer research communications · 2025
    Article
19. Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab.Journal of pharmaceutical analysis · 2025
    Article
20. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.Journal of hematology & oncology · 2025
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as